Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$2.94 USD
+0.20 (7.30%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $2.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
HOWL 2.94 +0.20(7.30%)
Will HOWL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOWL
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
Other News for HOWL
Optimistic Buy Rating for Werewolf Therapeutics Backed by Promising Early WTX-330 Trial Results
Where Werewolf Therapeutics Stands With Analysts
Buy Rating Affirmed for Werewolf Therapeutics Amid Promising WTX-330 Clinical Data and PREDATOR Platform Potential
Buy Rating Affirmed: Promising WTX-330 Trial Results and Strategic Partnerships Bolster Werewolf Therapeutics’ Outlook
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma